GlassScriptPhysician profile
Chetan P Patel
NPI 1639156516
$9,506.32
in general payments reported to CMS, 2019-2025
32 companies · $1,255 in 2025
The $1,255 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,547 · 2020: $1,721 · 2021: $1,037 · 2022: $1,182 · 2023: $900 · 2024: $863 · 2025: $1,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,019.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,152.75 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,139.89 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $795.69 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Abbott Laboratories | $739.56 | 2019-2025 | Mitraclip, Assurity |
| Abiomed | $611.88 | 2019-2025 | Impella |
| Pfizer INC. | $544.43 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $531.94 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $513.29 | 2021-2025 | Verquvo |
| Amgen INC. | $488.30 | 2019-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $457.98 | 2019-2020 | |
| Medtronic, INC. | $457.01 | 2022-2025 | Linq II, Cobalt Dr Mri Surescan, Micra |
| E.R. Squibb & Sons, L.L.C. | $370.33 | 2019-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $336.90 | 2019-2025 | General - Therapies, Watchman Flx |
| Janssen Pharmaceuticals, INC | $293.37 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $196.12 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $111.04 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Lundbeck LLC | $96.23 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $92.72 | 2024-2025 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $87.17 | 2022-2023 | |
| Arbor Pharmaceuticals, INC. | $68.05 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $62.19 | 2022-2023 | |
| Scpharmaceuticals INC. | $60.51 | 2023-2025 | |
| Philips North America LLC | $59.15 | 2020-2025 | Coronary Other |
| Lexicon Pharmaceuticals, INC. | $45.02 | 2023 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $39.24 | 2019-2020 | |
| Terumo Medical Corporation | $31.41 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $29.48 | 2019 | |
| Cvrx, INC. | $24.54 | 2025 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $23.20 | 2022 | |
| Atricure, INC. | $18.75 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $16.18 | 2024 | Arcalyst |
| Bardy Diagnostics, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chetan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.